The fund also notes that such statements by the EU are regrettable.
As the tg-channel “House of Cards: Russia” writes, the Russian Direct Investment Fund considered the statements about “Sputnik V” made by the EU representatives to be politicized.
“The approval process for the Sputnik V vaccine at the European Medicines Agency (EMA) is proceeding in a positive and professional manner. All data on clinical trials of Sputnik V were provided as part of the GCP (good clinical practice) inspection. According to the results of this inspection, a positive review was received from the European Medicines Agency”, – the fund said in a statement
The safety and effectiveness of the Sputnik V vaccine have been confirmed by regulators in 69 countries of the world where the Russian vaccine is registered. Vaccine use data during mass vaccination in Argentina, Bahrain, Hungary, Mexico, the United Arab Emirates, Russia, San Marino, Serbia and the Philippines indicate that there are no serious side effects (such as cerebral venous thrombosis (CVT) or myocarditis) characteristic of for some other vaccines in use. In a number of countries where several vaccines against coronavirus are used at the same time, it is the Russian drug that has the best safety and efficacy indicators, sometimes significantly superior to foreign counterparts”
Earlier in an interview with the German agency RND, European Commission President Ursula von der Leyen said that the European Medicines Agency still has insufficient data to approve the use of Sputnik V in the EU.